Please join us for a virtual symposium focused on therapeutics targeting LILRB (also known as ILT) receptors, an emerging class of “myeloid checkpoints” in cancer. We are bringing together leaders in the field to discuss: 1) seminal literature establishing a role for these receptors in cancer, 2) emerging clinical data for Merck’s MK-4830 (LILRB2 antibody) as presented at ESMO 2020 and recently published in Clinical Cancer Research, 3) emerging clinical and preclinical therapeutic pipeline. Our symposium is timely as it follows and will include discussion of new data expected at AACR (April 8-13). It also precedes and thus serves as a preview for several clinical data updates anticipated throughout 2022.
Dr. Tehila Ben Moshe, Chief Executive Officer; Ilana Mandel – VP research and development
-Immune-Onc Therapeutics Inc.
Charlene Liao, PhD – President & Chief Executive Officer; Paul Woodard, MD – Chief Medical Officer
-Jounce Therapeutics (JNCE)
Rich Murray, PhD – Chief Executive Officer; Beth Trehu, MD– Chief Medical Officer
-NGM Biopharmaceuticals (NGM)
David Woodhouse, PhD – Chief Executive Officer; Siobhan Nolan Mangini – Chief Financial Officer
Courtney Beers, PhD – Chief Scientific Officer
-Experts - Dr. J. Bryan Iorgulescu and Dr. Chengcheng (Alec) Zhang
Hosted by Raymond James Biotech Analyst Steve Seedhouse | Steve.Seedhouse@RaymondJames.com
*Upon registration you’ll receive a confirmation email with your dial-in details. Please add to your Outlook calendar for easy access to the call.